Sintilimab Plus Axitinib for Advanced Fumarate Hydratase–Deficient Renal Cell Carcinoma

What are the outcomes of sintilimab plus axitinib for treatment of patients with advanced fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC)?In this nonrandomized clinical trial, 41 patients with advanced FH-deficient RCC received at least 1 cycle of sintilimab plus axitinib. The objective response rate was 56%, with a median progression-free survival of 19.8 months and a manageable safety profile.These promising findings suggest that sintilimab plus axitinib warrants further investigation in patients with FH-deficient RCC.

Corresponding Author: Hao Zeng, MD, Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, China (kucaizeng@163.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.